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Editorial
Asymptomatic Microscopic Haematuria
and Significant Urinary Tract Disease
Richard T. Bryana,b and Roger C. Kockelberghb,c
aInstitute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
bAction Bladder Cancer UK, Tetbury, UK
cDepartment of Urology, University Hospitals of Leicester NHS Trust, Leicester, UK
Asymptomatic microscopic haematuria (AMH), or
non-visible haematuria (NVH), remains a conundrum
to primary and secondary care alike; is it a sign of
significant urinary tract disease, and does it require
urgent investigation? The wide variation in interna-
tional guidelines in defining who and when to refer
adds further to this confusion [1].
In this edition of Bladder Cancer, Ghandour et
al present their evaluation of haematuria in a large
public health care system in the USA [1] - Parkland
Health and Hospital Systems, comprising a central
hospital, 12 outpatient centres, 12 school-based clin-
ics, and 5 mobile vans. They retrospectively studied
a cohort of 11,422 patients ≥18 years of age and
with ≥3 red blood cells (RBCs) per high power field
(HPF) on urinalysis (UA) (some of whom had visi-
ble haematuria) in the outpatient clinic or emergency
room between January 2015 and April 2018; they
excluded patients with prior visits to any urology,
nephrology, or oncology clinics prior to the date of the
positive UA, patients with UA performed as an inpa-
tient, and patients with previous renal transplantation.
Their primary analysis excluded those patients ini-
tially diagnosed with a UTI. Their findings should be
considered in the context of the American Urological
Association (AUA) guidelines, defining microscopic
haematuria as ≥3 RBCs/HPF and strongly recom-
mending evaluation with cross-sectional imaging
using multiphasic computed tomography (CT) along
with cystoscopic evaluation of all patients aged ≥35
years without explained benign causes of the hema-
turia [2]. In the current study, over 83% of patients
were aged ≥35 years.
Only 11.4% of patients were referred to urology
and, of those referred, only 35% received complete
evaluation of haematuria (upper tract imaging and
cystoscopy). With regard to referral patterns, older
age, higher counts of RBCs/HPF on UA, hyperten-
sion, and repeated UA were all significant indepen-
dent predictors of referral to a urologist, whereas
female gender was a significant independent predic-
tor of failure to refer (OR = 0.31, p < 0.001). Of the
35% of referred patients who underwent complete
evaluation, females, younger patients, black patients,
and those patients with 3–19 RBCs/HPF (with the
latter group representing 87% of the cohort, or
9,933 patients) were less likely to undergo complete
evaluation.
Looking at the whole cohort, both referred and
not referred, urinary tract disease was subsequently
identified in 30% of patients; 3.7% of these patients
were diagnosed with malignancy (n = 130, 1.1% of
the whole cohort): 106 prostate cancers, 20 bladder
cancers, 3 kidney cancers and one upper tract urothe-
lial carcinoma (UTUC). All malignancies, except
53 prostate cancers, were diagnosed in the referred
group, giving a cancer detection rate of 5.9% in
those patients referred to urology, and a diagnosis
of significant urinary tract disease in a further 72%.
Focusing on the 24 cases of bladder cancer/kidney
cancer/UTUC, we see that 17 (71%) were diagnosed
in patients 35–65 years of age and 12 (50%) were
diagnosed in patients with 3–19 RBCs/HPF on UA;
17 of the 21 urothelial cancers (81%) were high grade.
Secondary analyses by the authors in UTI patients
with haematuria (n = 3241) identified a further 13
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cases of bladder cancer (0.4% of UTI patients with
haematuria), 9 of which occurred in patients <65
years of age (69%) and 7 of which occurred in patients
with 3–19 RBCs/HPF on UA (54%); 11 of these 13
cancers (85%) were high grade.
Aside from the key points made by the authors,
we note the poor rate of referral, despite clear guide-
lines from the AUA [2]. This is further accentuated in
female patients which, disappointingly, may demon-
strate entrenched assumptions of UTI as the cause
of haematuria (instead of significant other urinary
tract diseases, including malignancy), thus leading
to delayed diagnoses of malignancy [3]. Such delays
may result in the stage migration observed in female
bladder cancer patients compared to male patients
[4], and worse survival [5]. And as the Parkland data
also show, haematuria accompanying UTI does not
exclude the possibility of malignancy.
Given the differences in referral guidelines
between the UK and USA relating to age cut-offs
for the investigation of AMH, and the similarities
between the Parkland Health and Hospital Sys-
tem and the “average” UK National Health System
(NHS) hospital and its network, the cancer detection
rate of 5.9% in referred patients is comparable to
10.0–12.1% from UK data (13.8–18.9% for VH and
3.1–4.8% for NVH) [6, 7]. In line with the Parkland
data presented here, Tan et al. observed that in the
bladder cancers diagnosed following NVH, 59.4%
were high-risk cancers, with 31.3% being muscle-
invasive [7]. Importantly, in the Parkland cohort,
a further 72% of referred patients were diagnosed
with significant urinary tract disease ranging from
hydronephrosis to urolithiasis (albeit considerably
higher than observed in UK cohorts [6, 7]). Thus,
urology referral identified significant disease (includ-
ing malignancy) in the majority of patients, the vast
majority of whom had been referred due to AMH
and the majority of whom were <65 years old. This
is a clear message for primary care practitioners and
guideline committees.
Having established that AMH requires urologi-
cal referral and complete evaluation, what is the
urgency of referral and investigation? Bladder can-
cer patients already experience considerable delays
in their diagnostic and treatment pathways [8];
whether such delays significantly influence outcomes
remains complex and controversial (although the
findings of pathway delays and worse outcomes for
female patients remain consistent) [4]. In this regard,
haematuria risk scores may permit us to bridge the
gaps between primary care considerations, urolog-
ical cancer concerns, and patient preferences [7];
as Ghandour et al. highlight, such risk scores exist
and appear to have clear utility [9, 10]. In an era of
stratified and personalised medicine, surely such risk
scores must now become de rigeur [11]?
Perhaps in the near future, accessible, afford-
able, sensitive and specific non-invasive diagnostic
biomarkers may solve this conundrum and transform
haematuria referral decisions and subsequent treat-
ment and surveillance pathways [11–15]?
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